Search Results - "FURMAN, Wayne L"

“Trying to Be a Good Parent” As Defined By Interviews With Parents Who Made Phase I, Terminal Care, and Resuscitation Decisions for Their Children by Hinds, Pamela S, Oakes, Linda L, Hicks, Judy, Powell, Brent, Srivastava, Deo Kumar, Spunt, Sheri L, Harper, Joann, Baker, Justin N, West, Nancy K, Furman, Wayne L

“…When a child's cancer progresses beyond current treatment capability, the parents are likely to participate in noncurative treatment decision making. One…”
Get full text

Alveolar soft part sarcoma in children and young adults: A report of 69 cases by Flores, Ricardo J., Harrison, Douglas J., Federman, Noah C., Furman, Wayne L., Huh, Winston W., Broaddus, Emily G., Okcu, Mehmet F., Venkatramani, Rajkumar

“…Background Alveolar soft part sarcoma (ASPS) is a rare mesenchymal tumor characterized by ASPL‐TFE3 translocation. Apart from complete surgical resection,…”
Get full text

Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee by Katzenstein, Howard M., Furman, Wayne L., Malogolowkin, Marcio H., Krailo, Mark D., McCarville, M. Beth, Towbin, Alexander J., Tiao, Greg M., Finegold, Milton J., Ranganathan, Sarangarajan, Dunn, Stephen P., Langham, Max R., McGahren, Eugene D., Rodriguez‐Galindo, Carlos, Meyers, Rebecka L.

“…BACKGROUND The identification of new therapies for high‐risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum…”
Get full text

A mutational comparison of adult and adolescent and young adult (AYA) colon cancer by Tricoli, James V., Boardman, Lisa A., Patidar, Rajesh, Sindiri, Sivasish, Jang, Jin S., Walsh, William D., McGregor, Paul M., Camalier, Corinne E., Mehaffey, Michele G., Furman, Wayne L., Bahrami, Armita, Williams, P. Mickey, Lih, Chih‐Jian, Conley, Barbara A., Khan, Javed

“…BACKGROUND It is possible that the relative lack of progress in treatment outcomes among adolescent and young adult (AYA) patients with cancer is caused by a…”
Get full text

Treatment Outcomes in Black and White Children With Cancer: Results From the SEER Database and St Jude Children's Research Hospital, 1992 Through 2007 by PUI, Ching-Hon, DEQING PEI, JEHA, Sima, HUDSON, Melissa M, KUN, Larry E, MERCHANT, Thomas E, KOCAK, Mehmet, BRONISCER, Alberto, METZGER, Monika L, DOWNING, James R, WING LEUNG, EVANS, William E, PAPPO, Alberto S, GAJJAR, Amar, HOWARD, Scott C, CHENG CHENG, SANDLUND, John T, FURMAN, Wayne L, RIBEIRO, Raul C, SPUNT, Sheri L, RUBNITZ, Jeffrey E

“…Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts. We determined whether recent improved…”
Get full text

End-of-Life Care Preferences of Pediatric Patients With Cancer by HINDS, Pamela S, DREW, Donna, OAKES, Linda L, FOULADI, Maryam, SPUNT, Sheri L, CHURCH, Christopher, FURMAN, Wayne L

“…The viewpoint of the terminally ill child at the time of an end-of-life decision has not been formally investigated. We identified the preferences of children…”
Get full text

Decision Making by Parents of Children With Incurable Cancer Who Opt for Enrollment on a Phase I Trial Compared With Choosing a Do Not Resuscitate/Terminal Care Option by MAURER, Scott H, HINDS, Pamela S, SPUNT, Sheri L, FURMAN, Wayne L, KANE, Javier R, BAKER, Justin N

“…Parents of children with incurable cancer make complex and difficult decisions about remaining treatment options. We compared the self-reported rationale, good…”
Get full text

Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors by FOULADI, Maryam, LANINGHAM, Fred, GILBERTSON, Richard J, FURMAN, Wayne L, JIANRONG WU, O'SHAUGHNESSY, Melinda A, MOLINA, Kristen, BRONISCER, Alberto, SPUNT, Sheri L, LUCKETT, Inga, STEWART, Clinton F, HOUGHTON, Peter J

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic and pharmacodynamic properties of the mammalian target of…”
Get full text

Colorectal Carcinoma in Childhood and Adolescence: A Clinicopathologic Review by ASHLEY HILL, D, FURMAN, Wayne L, BILLUPS, Catherine A, RIEDLEY, Shannon E, CAIN, Alvida M, RAO, Bhaskar N, PRATT, Charles B, SPUNT, Sheri L

“…Pediatric colorectal carcinoma (CRC) is rare, but the available data suggest that it is more likely than adult CRC to be advanced at presentation and to have a…”
Get full text

A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors by Bishop, Michael W, Hutson, Paul R, Hank, Jacquelyn A, Sondel, Paul M, Furman, Wayne L, Meagher, Michael M, Navid, Fariba, Santana, Victor M

“…Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated…”
Get full text

Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy by Nguyen, Rosa, McCarville, M. Beth, Sykes, April, Mao, Shenghua, Wu, Jianrong, Langham, Max R., Furman, Wayne L.

“…Background Neoadjuvant chemotherapy is given to children with unresectable hepatoblastoma to increase the rate and safety of curative complete surgical…”
Get full text

Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma by Pai Panandiker, Atmaram S., Beltran, Chris, Billups, Catherine A., McGregor, Lisa M., Furman, Wayne L., Davidoff, Andrew M.

“…Background Locoregional failure is a significant concern in patients with high‐risk abdominal neuroblastoma (NB) receiving radiotherapy. Locoregional control…”
Get full text

Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial by Nguyen, Rosa, Sahr, Natasha, Sykes, April, McCarville, Mary Beth, Federico, Sara M, Sooter, Amanda, Cullins, David, Rooney, Barbara, Janssen, William E, Talleur, Aimee C, Triplett, Brandon M, Anthony, Gwendolyn, Dyer, Michael A, Pappo, Alberto S, Leung, Wing H, Furman, Wayne L

“…BackgroundNatural killer (NK) cells are one of the main effector populations of immunotherapy with monoclonal antibody and cytokines, used in combination with…”
Get full text

UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan by STEWART, Clinton F, PANETTA, John C, FURMAN, Wayne L, MCGREGOR, Lisa M, O'SHAUGHNESSY, Melinda A, THROM, Stacy L, FRAGA, Charles H, OWENS, Thandranese, TIEBIN LIU, BILLUPS, Catherine, RODRIGUEZ-GALINDO, Carlos, GAJJAR, Amar

“…To study the association between UDP-glucuronosyltransferase 1A1 (UGT1A1) genotypes and severe toxicity as well as irinotecan disposition in pediatric patients…”
Get full text

Bilateral Diffuse Nodular Pulmonary Ossification Mimicking Metastatic Disease in a Patient with Fibrolamellar Hepatocellular Carcinoma by Sutthatarn, Pattamon, Morin, Cara E, Gartrell, Jessica, Furman, Wayne L, Langham, Max R, Santiago, Teresa, Murphy, Andrew J

“…Pulmonary ossification (PO) is a rare finding, characterized by mature bone formation in the lung parenchyma. We report a 20-year-old female patient diagnosed…”
Get full text

Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors by FURMAN, Wayne L, NAVID, Fariba, GAJJAR, Amar J, HOUGHTON, Peter J, SANTANA, Victor M, STEWART, Clinton F, DAW, Najat C, MCCARVILLE, M. Beth, MCGREGOR, Lisa M, SPUNT, Sheri L, RODRIGUEZ-GALINDO, Carlos, PANETTA, John C, CREWS, Kristine R, JIANRONG WU

“…To assess the maximum-tolerated dosages (MTDs), and dose-limiting toxicities (DLTs) of the epidermal growth factor receptor inhibitor gefitinib and of…”
Get full text

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report by FOULADI, Maryam, FURMAN, Wayne L, WRIGHT, John, ADAMSON, Peter C, BLANEY, Susan M, CHIN, Thomas, FREEMAN, Burgess B, DUDKIN, Lorina, STEWART, Clinton F, KRAILO, Mark D, SPEIGHTS, Roseanne, INGLE, Ashish M, HOUGHTON, Peter J

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase…”
Get full text

A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors by Hoffer, Fredric A., Daw, Najat C., Xiong, Xiaoping, Anghelescu, Doralina, Krasin, Matthew, Yan, Xiaowei, Davidoff, Andrew M., Furman, Wayne L., Rodriguez‐Galindo, Carlos, Spunt, Sheri L.

“…BACKGROUND: This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric…”
Get full text

Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma by Venkatramani, Rajkumar, Furman, Wayne L., Fuchs, Joerg, Warmann, Steven W., Malogolowkin, Marcio H.

“…Hepatoblastoma is the most common primary malignant neoplasm of the liver in children. Improvements in chemotherapy and surgical techniques have increased…”
Get full text

Disease control intervals in high‐risk neuroblastoma by Santana, Victor M., Furman, Wayne L., McGregor, Lisa M., Billups, Catherine A.

“…BACKGROUND. Current salvage therapy for recurrent high‐risk neuroblastoma is rarely curative. Assessment of the effectiveness of new, primarily cytostatic…”
Get full text